
The FDA in September approved the supplemental new drug application of NovoLog, a rapid acting form of insulin for the control of hyperglycemia in patients with type 1 and type 2 diabetes. Manufactured by Novo Nordisk Inc., NovoLog can be administered immediately before a meal.